Statements (59)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:Company
|
gptkbp:bfsLayer |
3
|
gptkbp:bfsParent |
gptkb:Company
|
gptkbp:brand |
gptkb:Novo_Log
|
gptkbp:clinical_trial |
insulin pump therapy
studied for efficacy studied for safety mealtime insulin |
gptkbp:contraindication |
severe hypoglycemia
hypersensitivity to insulin aspart |
gptkbp:dosage_form |
solution for injection
|
gptkbp:duration |
3 to 5 hours
|
gptkbp:education |
insulin administration techniques
diet and exercise recommendations hypoglycemia management |
gptkbp:effective_date |
gptkb:2000
|
gptkbp:form |
vials
pre-filled pens |
gptkbp:formulation |
injectable solution
|
gptkbp:highest_point |
1 to 3 hours
|
https://www.w3.org/2000/01/rdf-schema#label |
Novolog
|
gptkbp:ingredients |
gptkb:insulin_aspart
|
gptkbp:interacts_with |
gptkb:beer
beta-blockers thiazide diuretics |
gptkbp:invention |
patented
generic versions available |
gptkbp:is_monitored_by |
blood glucose levels
Hb A1c levels |
gptkbp:is_used_for |
diabetes management
|
gptkbp:manager |
subcutaneous injection
|
gptkbp:manufacturer |
gptkb:Novo_Nordisk
|
gptkbp:marketed_as |
gptkb:legislation
gptkb:United_States gptkb:Native_American_tribe |
gptkbp:packaging |
multi-dose vials
single-dose pens |
gptkbp:pharmacokinetics |
rapid-acting insulin
absorbed quickly peak effect within 1-3 hours |
gptkbp:population |
Type 1 diabetes patients
Type 2 diabetes patients |
gptkbp:premiered_on |
10 to 20 minutes
|
gptkbp:price |
varies by region
insurance coverage may apply |
gptkbp:products |
gptkb:Fiasp
gptkb:Novo_Log_Mix_70/30 |
gptkbp:provides_information_on |
EASD guidelines
ADA guidelines |
gptkbp:regulatory_compliance |
FDA approved
EMA approved |
gptkbp:safety_features |
dispose of needles properly
do not share pens monitor for hypoglycemia |
gptkbp:scholarships |
available through manufacturer
|
gptkbp:side_effect |
weight gain
injection site reactions hypoglycemia |
gptkbp:storage |
refrigerated
|